Other languages Cocrystal Pharma, Inc.

Equities

COCP

US19188J4094

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-22 pm EDT			5-day change	1st Jan Change
1.52 ^USD	-0.65%		+7.96%	-11.74%

Mar. 28	Cocrystal Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Jan. 04	Cocrystal Pharma, Inc. Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investment Candidates	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cocrystal Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28
Cocrystal Pharma, Inc. Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investment Candidates	Jan. 04
Top Premarket Gainers	Dec. 07
Cocrystal Pharma, Inc. Announces First-Patient-In for Phase 2A Human Challenge Study Evaluating Oral Cc-42344 in Pandemic and Seasonal Influenza A	Dec. 06
Cocrystal Pharma, Inc. Highlights Its Novel Inhaled and Oral Influenza A Antiviral Cc-42344 At the World Vaccine Congress West Coast	Nov. 29
Cocrystal Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13
Cocrystal Pharma, Inc. Doses First Subjects in Clinical Study of CDI-988 for Pandemic Norovirus and Coronavirus	23-09-28
Cocrystal Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14
Cocrystal Pharma Files $150 Million Mixed Shelf	23-05-25
Cocrystal Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15
Cocrystal Pharma Files $150 Million Mixed Shelf	23-05-15
Cocrystal Pharma, Inc. Appoints Fred Hassan to Its Board of Directors	23-04-24
Insider Buy: Cocrystal Pharma	23-04-06
Cocrystal Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-29
Cocrystal Pharma Says Study of Antiviral Treatment for Influenza A Showed Mild Adverse Events	22-12-19
Cocrystal Pharma Reports Highly Favorable Safety and Tolerability Results from a Phase 1 Study with its Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A	22-12-19
CoCrystal Pharma, Inc. Highlights Progress with CC-42344 as Potential Oral Treatment for Pandemic and Seasonal Influenza A at World Antiviral Congress 2022	22-12-01
Cocrystal Pharma, Inc. Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A	22-11-17
Cocrystal Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14
Cocrystal Pharma, Inc. Announces Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma's Oral Antiviral Candidate Cc-42344	22-10-26

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Cocrystal Pharma, Inc.

Equities

COCP

US19188J4094

Other languages

Filters